PCSK9 inhibitors
PCSK9 inhibitors are cholesterol medicines that block a protein called PCSK9. MedlinePlus says this helps the liver remove and clear LDL cholesterol from the blood. The US labels of alirocumab and evolocumab each call the product a PCSK9 inhibitor, and both have their own pages. A third cholesterol medicine acts on the messenger RNA for PCSK9 instead and is linked here, not filed under the class. This is the class page.
Also called Proprotein convertase subtilisin kexin type 9 inhibitors
- Drug
- In this atlas
Overview
Technical summary
Class page. MeSH descriptor D000091362 (PCSK9 Inhibitors, lastUpdated 2022-01-01) is an exact match; its scope note says these agents inhibit the PCSK9 enzyme, which has an important role in degrading LDL (LDL cholesterol) receptors, and that they favor LDL catabolism and lower plasma LDL cholesterol. The US labels read for alirocumab (BLA125559) and evolocumab (BLA125522) call each product a PCSK9 inhibitor, and RxClass lists the established pharmacologic class PCSK9 Inhibitor on US drug labels for both (read 2026-11-18); alirocumab and evolocumab are filed under this page on that evidence. The US label of a third PCSK9-directed medicine (NDA214012), a small interfering RNA, says it directs breakdown of the mRNA for PCSK9, and RxClass returned no class for it, so it has a related link only. MedlinePlus names these medicines together with another cholesterol class that has its own page. No trial result and no dose is recorded.
Drugs in this class
2 drugs in this atlas are filed under PCSK9 inhibitors, with the registry trials and FDA regulatory decisions this atlas holds for each. With PCSK9 inhibitors itself, the class has 74 distinct trials and 16 distinct FDA decisions; a trial or decision that two of them share counts once there.
About this drug
- Level
- Class
- Mechanism
- MedlinePlus says these medicines block a protein called PCSK9, which helps the liver remove and clear LDL cholesterol from the blood; MeSH says they favor LDL (LDL cholesterol) catabolism and lower plasma LDL cholesterol.
Claims and evidence
No claims are published for this drug yet.
Record details
- Record id
cardio:pcsk9-inhibitors- Content hash
00f20ae3bab6714ae2340cf5380f759c81f3889640244a3657f39ef375a337a1